Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol

FDA approval extends the indication of Evkeeza to treat younger patients with homozygous hypercholesterolemia (HoFH) HoFH is an inherited ...

F.D.A.’s Approval of a Drug for Autism Upends Review Process

The agency expanded use of an old drug as a treatment for some people with autism. The endorsement sent some customers ...
The American Journal of Managed Care

FDA Expands Evinacumab-dgnb Approval for Children as Young as 1 Year With HoFH

Regeneron Pharmaceuticals, Inc., announced FDA approval of evinacumab-dgnb (Evkeeza) for children as young as 1 year of age with homozygous familial hypercholesterolemia (HoFH), expanding treatment ...
Pharmaceutical Technology on MSN

Regeneron’s Evkeeza gains FDA approval for young HoFH patients

The US FDA has expanded the approval of Regeneron Pharmaceuticals' fully human monoclonal antibody, Evkeeza (evinacumab-dgnb) ...
Morningstar

U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease

− Approval Expands Use of VONVENDI to Include Routine Prophylaxis to Reduce the Frequency of Bleeding Episodes in Adults with Type 1 and 2 Von Willebrand Disease (VWD) and On-Demand and Perioperative ...

DWP update as £150 Warm Home Discount to be 'expanded'

The Warm Home Discount is a one-off £150 discount off your electricity bill. The payment was previously mostly available in ...
PharmExec

Regeneron’s Evkeeza Approved in U.S. for Young Children with Homozygous Familial Hypercholesterolemia

Regeneron's Evkeeza gains FDA approval for treating young children with homozygous familial hypercholesterolemia, addressing ...
MPR

Evkeeza Approval Expanded to Include Younger HoFH Patients

The Food and Drug Administration (FDA) has expanded the approval of Evkeeza ® (evinacumab-dgnb) to include children aged 1 year and older with homozygous familial hypercholesterolemia (HoFH).
Morningstar

STANDARD FLEET SECURES $13M SERIES A TO POWER MIXED-FLEET CONNECTIVITY, LAUNCHES EXPANDED DIGITAL KEY PLATFORM

SAN FRANCISCO, Sept. 10, 2025 /PRNewswire/ -- Standard Fleet, a fleet management platform for the connected-vehicle era, has raised $13 million in Series A funding and expanded its hardware-free ...

Regeneron Pharmaceuticals, Inc.: Evkeeza (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol

FDA approval extends the indication of Evkeeza to treat younger patients with homozygous hypercholesterolemia (HoFH) HoFH is an inherited condition characterized by extremely high levels of low-densit ...